Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00505713 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study Using Rexin-G for Sarcoma

A Phase 1 study of Sarcoma, sponsored by Epeius Biotechnologies.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
2
Study locations

NCT00505713: Completed Phase 1 study of Sarcoma, sponsored by Epeius Biotechnologies.

NCT00505713 is a Phase 1 study of Sarcoma that has completed, run by Epeius Biotechnologies. The registered enrollment target is 36 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00505713, a Phase 1 study of Sarcoma, has completed, sponsored by Epeius Biotechnologies.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
2
Study locations

Study Summary

Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions, thus enhancing local drug concentration within tumors. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.

Conditions Studied

Sarcoma

Interventions

  • GENETIC Rexin-G

Study Locations (2)

California

  • Epeius Clinical Research Unit - San Marino
  • Sarcoma Oncology Center - Santa Monica

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2007-07
Est. Completion 2011-06
Phase Phase 1
Epeius Biotechnologies

5 total trials

What the finished NCT00505713 record still lists

NCT00505713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Rexin-G is the first listed.

NCT00505713 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00505713 about?

NCT00505713 is a clinical study titled "Safety and Efficacy Study Using Rexin-G for Sarcoma". Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions, thus enhancing local drug concentration within tumors. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to...

What is the current status of trial NCT00505713?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2011-06.

What conditions does trial NCT00505713 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00505713?

The interventions under investigation include: Rexin-G (GENETIC).

Who is sponsoring clinical trial NCT00505713?

This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00505713 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00505713's enrollment target sits among peer trials

36 79th of 122 higher than 43 of 122 other Sarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00505713, the US trial registry maintained by the National Library of Medicine. NCT00505713 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.